- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06098651 | A Study of DCR-STAT3 in Adults With Solid Tumors | completed | Phase 1 | 26 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04221204 | A Monotherapy in Subjects With Advanced Solid Tumors | completed | Phase 1 | 23 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05864144 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 / Phase 2 |
| 98 |
| Sensei Biotherapeutics, Inc.INDUSTRY |
| 1 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06614140 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 8 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT05763004 | A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | completed | Phase 1 | 47 | ImmunOs Therapeutics AGINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05620472 | Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05723640 | The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | completed | Phase 1 | 11 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05114668 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1(NYM) | completed | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04306900 | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | completed | Phase 1 | 185 | Trishula Therapeutics, Inc.INDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 192 | Taiho Oncology, Inc.INDUSTRY | 4 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03990233 | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | completed | Phase 1 | 100 | OSE ImmunotherapeuticsINDUSTRY | 2 | Jun 26, 2025 | clinicaltrials |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | completed | Phase 1 | 41 | Relay Therapeutics, Inc.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
| NCT04105335 | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)(TIMEPOINT) | completed | Phase 1 | 50 | Mina Alpha LimitedINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03441100 | TCR-engineered T Cells in Solid Tumors: IMA202-101(ACTengine) | completed | Phase 1 | 16 | Immatics US, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03628677 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | completed | Phase 1 | 75 | Arcus Biosciences, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03922204 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | completed | Phase 1 | 72 | Merus B.V.INDUSTRY | 4 | Dec 11, 2024 | clinicaltrials |
| NCT04020185 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | completed | Phase 1 / Phase 2 | 40 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05018273 | Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors | completed | Phase 1 | 26 | Nykode Therapeutics ASAINDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT05990920 | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | completed | Phase 1 | 6 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT00483366 | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 13 | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03516123 | A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 18 | CStone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03523819 | A Study of CS1002 in Subjects with Advanced Solid Tumors | completed | Phase 1 | 91 | CStone PharmaceuticalsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT03873883 | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer(IO-001) | completed | Phase 1 | 119 | iTeos TherapeuticsINDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05117177 | New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer | completed | Phase 1 | 57 | iTeos TherapeuticsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04121442 | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 15 | Buzzard PharmaceuticalsINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT05054348 | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | completed | Phase 1 | 91 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05309187 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | completed | Phase 1 | 22 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT00020371 | BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05078593 | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma | completed | Phase 1 | 18 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03728179 | RACIN in Patients With Advanced TIL-negative Solid Tumors(RACIN) | completed | Phase 1 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 20, 2024 | clinicaltrials |
Data updated yesterdaySource updated Sep 29, 2026source: clinicaltrials